Full Text View
Tabular View
No Study Results Posted
Related Studies
Functional Magnetic Resonance Imaging (MRI) Before and After Treatment for Depression
This study is currently recruiting participants.
Verified by Stanford University, May 2009
First Received: May 7, 2009   Last Updated: May 8, 2009   History of Changes
Sponsored by: Stanford University
Information provided by: Stanford University
ClinicalTrials.gov Identifier: NCT00896441
  Purpose

The purpose of this study is to help us understand how depression changes brain activity and how this relates to mood, anxiety, and cognitive functions like memory. The investigators also hope to develop a brain imaging test that will predict either before or within two weeks of starting a medicine whether the treatment will work.


Condition Intervention
Depression
Depressive Disorder
Mood Disorders
Drug: Celexa
Other: Magnetic Resonance Imaging (MRI)

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study
Official Title: Functional MRI Before and After Treatment for Depression

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Hamilton for Depression
  • Hamilton for Anxiety
  • Neuropsychiatric Assessments

Estimated Enrollment: 60
Study Start Date: February 2009
Estimated Study Completion Date: February 2012
Estimated Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Patients will be aged 18-55, have no significant neurologic history, must meet DSM-IV criteria for a diagnosis of major depression and be free of antidepressant or other psychotropic medication for a minimum of two weeks before enrollment.
  2. If a subject is talking psychiatric medication he/she may be weaned off of the medication by their treating physician prior to study enrollment. Such a course of action would only be advised if the current medication was not considered to be of any benefit to the subject.
  3. In particular, if a patient is on antidepressant medication which is of benefit, we would not advise tapering off medication -- and subsequent risk of relapse -- in order to participate in the study. The same line of thinking applies to all psychiatric diagnoses and associated medications candidate subjects may be taking.

Exclusion Criteria:

  1. Significant head trauma with loss of consciousness.
  2. Active abuse of alcohol or illegal substances.
  3. Excluded psychiatric diagnoses include: Bipolar Affective Disorder, primary psychotic disorders (Schizophrenia, Schizoaffective disorder), Obsessive-Compulsive Disorder.
  4. Pregnant or nursing women.
  5. Any contraindication to being scanned in the 3T scanner at the Lucas Center such as having a pacemaker.

    or any implanted device that has not been cleared for scanning at 3 Tesla.

  6. Any significant neurologic history (i.e., seizure, stroke, multiple sclerosis).
  7. Use of psychotropic medications within 2 weeks of enrollment.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00896441

Contacts
Contact: Maureen H Chang, B.S. 7254620 mhchang@stanford.edu

Locations
United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Maureen H Chang, B.S.     7254620     mhchang@stanford.edu    
Contact: Jessica Hawkins, B.S.     7238323     jhawk@stanford.edu    
Principal Investigator: Michael D Greicius            
Sub-Investigator: Charles DeBattista            
Sub-Investigator: Matthew White            
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Michael D Greicius Stanford University
  More Information

No publications provided

Responsible Party: Stanford University School of Medicine ( Michael D Greicius, Principal Investigator )
Study ID Numbers: SU-04202009-2339, 15305
Study First Received: May 7, 2009
Last Updated: May 8, 2009
ClinicalTrials.gov Identifier: NCT00896441     History of Changes
Health Authority: United States: Institutional Review Board

Study placed in the following topic categories:
Depression
Mental Disorders
Mood Disorders
Dexetimide
Depressive Disorder
Citalopram
Behavioral Symptoms

Additional relevant MeSH terms:
Pathologic Processes
Disease
Depression
Mental Disorders
Mood Disorders
Depressive Disorder
Behavioral Symptoms

ClinicalTrials.gov processed this record on September 10, 2009